Dermatitis Herpetiformis Market, By Drug Class, By Route of Administration, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

Description

REPORT HIGHLIGHT

Dermatitis Herpetiformis Market size was valued at USD 301.03 Million in 2023, expanding at a CAGR of 7.29% from 2024 to 2032.

Dermatitis herpetiformis is a skin condition that causes itchy, blistering rashes. Dermatitis herpetiformis is linked to celiac disease, so it often occurs in people who cannot eat gluten, a protein found in wheat. When someone with celiac disease eats gluten, their body reacts by causing this skin rash. The rash usually appears on the elbows, knees, and buttocks but can show up anywhere on the body.

Treatment typically involves a strict gluten-free diet, which helps reduce symptoms and prevent future outbreaks. Medications can also be used to relieve itching and inflammation. Early diagnosis and proper management are important to improve the quality of life for those affected.

Dermatitis Herpetiformis Market- Market Dynamics

Growing awareness of gluten sensitivity and its skin manifestations drives demand.

The growing awareness of gluten sensitivity and its link to skin conditions like dermatitis herpetiformis (DH) is a key driver for the market. More people are recognizing the symptoms of gluten intolerance, which is increasing the demand for tests and treatments for DH. The National Institutes of Health (NIH) states that about 1 in 141 people in the U.S. has celiac disease, closely related to DH. This rising awareness encourages both healthcare providers and patients to seek better testing and management options. As a result, pharmaceutical companies and health organizations are focusing on developing specific treatments and educational materials to help address this condition, boosting market growth.

Dermatitis Herpetiformis Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.29% over the forecast period (2024-2032)

Based on Drug Class segmentation, Dapsone was predicted to show maximum market share in the year 2023

Based on Route of Administration segmentation, Oral was the leading type in 2023

Based on End Users, Hospitals was the leading type in 2023

based on Region, North America was the leading revenue generator in 2023

Dermatitis Herpetiformis Market- Segmentation Analysis:

The Global Dermatitis Herpetiformis Market is segmented based on Drug Class, Route of Administration, End User, and Region.

The market is divided into three categories based on Drug Class: Dapsone, Topical corticosteroids, and Antihistamines. Dapsone is the most significant. Dapsone is an antibiotic that helps reduce itching and inflammation associated with the condition. It works effectively to clear up skin lesions, making it a preferred choice for many doctors. Its quick action and ability to provide relief from symptoms make it stand out in the treatment options. Dapsone's effectiveness leads to its wide use and recommendation, driving its prominence in the dermatitis herpetiformis market.

The market is divided into two categories based on the Route of Administration: Oral, Topical, and Injectable. The oral route of administration is the most significant and prominent. This is because oral medications, like dapsone and other treatments, are convenient to take and offer effective relief from symptoms. Patients prefer oral treatments since they are convenient and non-invasive, making it simpler to manage the condition over time. Injectable and topical options are available, but they are less favored due to factors like discomfort or the need for more frequent applications. Overall, oral medications play a key role in managing dermatitis herpetiformis effectively.

Dermatitis Herpetiformis Market- Geographical Insights

The North American Dermatitis Herpetiformis market is important because of the high number of autoimmune diseases and greater awareness of skin conditions. The United States leads this market, thanks to its advanced healthcare system and strong research efforts.

More innovative treatments and therapies are becoming available, backed by many clinical trials and approvals. Canada also plays a role in market growth by focusing on patient education and support. With many major pharmaceutical companies in the region, there's a lot of collaboration and innovation.

Dermatitis Herpetiformis Market- Competitive Landscape:

The Dermatitis Herpetiformis market is competitive, with several key players involved. Major companies like GlaxoSmithKline, AbbVie, and Novartis develop treatments for autoimmune skin diseases. They invest in research to improve existing therapies and create new ones. Firms like Pfizer and Johnson & Johnson also contribute innovative products to the market.

Furthermore, smaller companies like Aclaris Therapeutics are seeing growth by specializing in niche treatments. Overall, the landscape is dynamic, driven by collaboration and innovation to enhance the management of Dermatitis herpetiformis.

Recent Developments:

In May 2023, AbbVie's aesthetics division expanded its product lineup with a recent FDA approval for a new product called Skinvive. This approval, granted this week, added to Allergan's Juvederm dermal filler range.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DERMATITIS HERPETIFORMIS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

GlaxoSmithKline
AbbVie
Amgen
Celgene (Bristol-Myers Squibb)
Novartis
Pfizer
Johnson & Johnson
Mylan
Takeda Pharmaceuticals
AstraZeneca
Regeneron Pharmaceuticals
Sanofi
Eli Lilly and Company
Dermira
Aclaris Therapeutics
Incyte Corporation
Teva Pharmaceutical Industries

GLOBAL DERMATITIS HERPETIFORMIS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

Dapsone
Topical corticosteroids
Antihistamines

GLOBAL DERMATITIS HERPETIFORMIS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

Oral
Topical
Injectable

GLOBAL DERMATITIS HERPETIFORMIS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

Hospitals
Dermatology Clinics
Homecare Settings
Others

GLOBAL DERMATITIS HERPETIFORMIS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

Product Code: ANV3932

1. Dermatitis Herpetiformis Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Dermatitis Herpetiformis Market Snippet by Drugs Class
- 2.1.2. Dermatitis Herpetiformis Market Snippet by Route of Administration
- 2.1.3. Dermatitis Herpetiformis Market Snippet by End User
- 2.1.4. Dermatitis Herpetiformis Market Snippet by Country
- 2.1.5. Dermatitis Herpetiformis Market Snippet by Region
2.2. Competitive Insights

3. Dermatitis Herpetiformis Key Market Trends

3.1. Dermatitis Herpetiformis Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Dermatitis Herpetiformis Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Dermatitis Herpetiformis Market Opportunities
3.4. Dermatitis Herpetiformis Market Future Trends

4. Dermatitis Herpetiformis Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Dermatitis Herpetiformis Market: COVID-19 Impact Analysis

5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments

6. Dermatitis Herpetiformis Market Landscape

6.1. Dermatitis Herpetiformis Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Dermatitis Herpetiformis Market - By Drugs Class

7.1. Overview
- 7.1.1. Segment Share Analysis, By Drugs Class, 2023 & 2032 (%)
7.2. Dapsone
7.3. Topical corticosteroids
7.4. Antihistamines

8. Dermatitis Herpetiformis Market - By Route of Administration

8.1. Overview
- 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
- 8.1.2. Oral
- 8.1.3. Topical
- 8.1.4. Injectable

9. Dermatitis Herpetiformis Market - By End User

9.1. Overview
- 9.1.1. Segment Share Analysis, By End User, 2023 & 2032 (%)
- 9.1.2. Hospitals
- 9.1.3. Dermatology Clinics
- 9.1.4. Homecare Settings
- 9.1.5. Others

10. Dermatitis Herpetiformis Market- By Geography

10.1. Introduction
- 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
10.2. North America
- 10.2.1. Overview
- 10.2.2. Dermatitis Herpetiformis Key Manufacturers in North America
- 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.2.4. North America Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
- 10.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.2.6. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.2.7. U.S.
  - 10.2.7.1. Overview
  - 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.7.3. U.S. Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.2.7.5. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.2.8. Canada
  - 10.2.8.1. Overview
  - 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.8.3. Canada Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.2.8.5. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.3. Europe
- 10.3.1. Overview
- 10.3.2. Dermatitis Herpetiformis Key Manufacturers in Europe
- 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.3.4. Europe Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
- 10.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.3.6. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.7. Germany
  - 10.3.7.1. Overview
  - 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.7.3. Germany Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.3.7.5. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.8. Italy
  - 10.3.8.1. Overview
  - 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.8.3. Italy Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.3.8.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.3.8.5. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.9. United Kingdom
  - 10.3.9.1. Overview
  - 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.9.3. United Kingdom Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.3.9.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.3.9.5. United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.10. France
  - 10.3.10.1. Overview
  - 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.10.3. France Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.3.10.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.3.10.5. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.11. Russia
  - 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.11.2. Russia Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.3.11.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.3.11.4. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.12. Netherlands
  - 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.12.2. Netherlands Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.3.12.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.3.12.4. Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.13. Sweden
  - 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.13.2. Sweden Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.3.13.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.3.13.4. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.14. Poland
  - 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.14.2. Poland Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.3.14.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.3.14.4. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.15. Rest of Europe
  - 10.3.15.1. Overview
  - 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.3.15.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.3.15.5. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.4. Asia Pacific (APAC)
- 10.4.1. Overview
- 10.4.2. Dermatitis Herpetiformis Key Manufacturers in Asia Pacific
- 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.4.4. Asia Pacific Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
- 10.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.4.6. Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.7. India
  - 10.4.7.1. Overview
  - 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.7.3. India Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.4.7.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.4.7.5. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.8. China
  - 10.4.8.1. Overview
  - 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.8.3. China Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.4.8.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.4.8.5. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.9. Japan
  - 10.4.9.1. Overview
  - 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.9.3. Japan Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.4.9.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.4.9.5. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.10. South Korea
  - 10.4.10.1. Overview
  - 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.10.3. South Korea Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.4.10.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.4.10.5. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.11. Australia
  - 10.4.11.1. Overview
  - 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.11.3. Australia Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.4.11.5. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.12. Thailand
  - 10.4.12.1. Overview
  - 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.12.3. Thailand Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.4.12.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.4.12.5. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.13. Indonesia
  - 10.4.13.1. Overview
  - 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.13.3. Indonesia Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.4.13.5. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.14. Philippines
  - 10.4.14.1. Overview
  - 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.14.3. Philippines Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.4.14.5. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.15. Rest of APAC
  - 10.4.15.1. Overview
  - 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.15.3. Rest of APAC Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.4.15.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.4.15.5. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.5. Latin America
- 10.5.1. Overview
- 10.5.2. Dermatitis Herpetiformis Key Manufacturers in Latin America
- 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.5.4. Latin America Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
- 10.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.5.6. Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.5.7. Brazil
  - 10.5.7.1. Overview
  - 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.7.3. Brazil Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.5.7.5. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.5.8. Mexico
  - 10.5.8.1. Overview
  - 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.8.3. Mexico Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.5.8.5. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.5.9. Argentina
  - 10.5.9.1. Overview
  - 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.9.3. Argentina Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.5.9.5. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.5.10. Colombia
  - 10.5.10.1. Overview
  - 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.10.3. Colombia Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.5.10.5. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.5.11. Rest of LATAM
  - 10.5.11.1. Overview
  - 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.5.11.5. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.6. Middle East and Africa
- 10.6.1. Overview
- 10.6.2. Dermatitis Herpetiformis Key Manufacturers in Middle East and Africa
- 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.6.4. Middle East and Africa Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
- 10.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.6.6. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.7. Saudi Arabia
  - 10.6.7.1. Overview
  - 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.6.7.5. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.8. United Arab Emirates
  - 10.6.8.1. Overview
  - 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.6.8.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.6.8.5. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.9. Israel
  - 10.6.9.1. Overview
  - 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.9.3. Israel Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.6.9.5. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.10. Turkey
  - 10.6.10.1. Overview
  - 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.10.3. Turkey Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.6.10.5. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.11. Algeria
  - 10.6.11.1. Overview
  - 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.11.3. Algeria Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.6.11.5. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.12. Egypt
  - 10.6.12.1. Overview
  - 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.12.3. Egypt Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.6.12.5. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.13. Rest of MEA
  - 10.6.13.1. Overview
  - 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.13.3. Rest of MEA Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.6.13.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.6.13.5. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Dermatitis Herpetiformis Industry

11.1. Competitive Dashboard
11.2. Company Profiles
- 11.2.1. GlaxoSmithKline
- 11.2.2. AbbVie
- 11.2.3. Amgen
- 11.2.4. Celgene (Bristol-Myers Squibb)
- 11.2.5. Novartis
- 11.2.6. Pfizer
- 11.2.7. Johnson & Johnson
- 11.2.8. Mylan
- 11.2.9. Takeda Pharmaceuticals
- 11.2.10. AstraZeneca
- 11.2.11. Regeneron Pharmaceuticals
- 11.2.12. Sanofi
- 11.2.13. Eli Lilly and Company
- 11.2.14. Dermira
- 11.2.15. Aclaris Therapeutics
- 11.2.16. Incyte Corporation
- 11.2.17. Teva Pharmaceutical Industries

12. 360 Degree Analyst View

13. Appendix

13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us